Guthrie R
Department of Emergency Medicine, Ohio State University, Columbus.
J Fam Pract. 1994 Aug;39(2):129-33.
Terazosin, an alpha 1 blocker initially used as an antihypertensive, was approved in 1993 for use in the treatment of benign prostatic hyperplasia (BPH) symptoms. This study was designed to determine the safety and efficacy of terazosin in treating patients with concomitant BPH and hypertension.
Middle-aged men with essential hypertension were enrolled by their primary care physicians in community practice. Those with symptoms of benign prostatic hyperplasia were identified by a Boyarsky scale score. The study was a 12-week, dose-escalation, open-label protocol for men aged 45 years and older.
Enrollment in the study totaled 5365 patients. Of these, 1483 had Boyarsky scores of > or = 7, indicating symptomatic BPH. All patients with elevated blood pressure at the beginning of the study, including those with symptomatic BPH, showed significant reduction in blood pressure at the end of the 12-week trial. The patients with symptomatic BPH had statistically significant improvement in their BPH voiding symptoms. In the 1483 patients with BPH symptoms, terazosin produced a mean reduction of 55% in overall Boyarsky scores, 57% in obstructive symptom scores, and 54% in irritative symptom scores. In patients with baseline blood pressure < or = 150/90 mm Hg, blood pressure reductions were statistically significant but clinically irrelevant. Adverse events were mild.
Terazosin is safe and effective in treating concomitant hypertension and BPH.
特拉唑嗪是一种最初用作抗高血压药物的α1阻滞剂，于1993年被批准用于治疗良性前列腺增生（BPH）症状。本研究旨在确定特拉唑嗪治疗合并BPH和高血压患者的安全性和有效性。
社区实践中的初级保健医生招募患有原发性高血压的中年男性。通过博亚尔斯基量表评分识别出有良性前列腺增生症状的患者。该研究是一项针对45岁及以上男性的为期12周、剂量递增、开放标签的方案。
共有5365名患者参与该研究。其中，1483名患者的博亚尔斯基评分≥7，表明有症状性BPH。在研究开始时所有血压升高的患者，包括有症状性BPH的患者，在12周试验结束时血压均显著降低。有症状性BPH的患者其BPH排尿症状有统计学意义的改善。在1483名有BPH症状的患者中，特拉唑嗪使总体博亚尔斯基评分平均降低55%，梗阻性症状评分降低57%，刺激性症状评分降低54%。在基线血压≤150/90 mmHg的患者中，血压降低有统计学意义但临床意义不大。不良事件轻微。
特拉唑嗪治疗合并高血压和BPH安全有效。
